Drug Type Small molecule drug |
Synonyms |
Target |
Action antagonists, modulators |
Mechanism GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists), NMDA receptor modulators(Glutamate [NMDA] receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 2 | Belgium | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | Belgium | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | United States | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | Japan | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | Bulgaria | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | Czechia | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | Bulgaria | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | Czechia | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | United States | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | Germany | 27 Mar 2024 |